Cargando…

The emergence of new SARS-CoV-2 omicron subvariants introduces uncertainty about the end of the COVID-19 pandemic

Detalles Bibliográficos
Autor principal:	da Silva, Severino Jefferson Ribeiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590648/ https://www.ncbi.nlm.nih.gov/pubmed/36300185 http://dx.doi.org/10.3389/fmed.2022.1010489

Ejemplares similares

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Immune Evasion of SARS-CoV-2 Omicron Subvariants
por: Ke, Hanzhong, et al.
Publicado: (2022)

Recent insights into SARS‐CoV‐2 omicron variant
por: da Silva, Severino Jefferson Ribeiro, et al.
Publicado: (2022)

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants
por: Cho, Junhyung, et al.
Publicado: (2023)

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants
por: da Silva, Severino Jefferson Ribeiro, et al.
Publicado: (2022)

Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
por: Moriyama, Miyu, et al.
Publicado: (2023)

Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the host
por: Tang, Haijun, et al.
Publicado: (2023)

The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity
por: DeGrasse, David C, et al.
Publicado: (2023)

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
por: Ito, Jumpei, et al.
Publicado: (2023)

Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients
por: Deng, Haohui, et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Comparison of the replication and neutralization of different SARS‐CoV‐2 Omicron subvariants in vitro
por: Zhang, Yaqing, et al.
Publicado: (2023)

Correction: The Rise of SARS-CoV-2 (COVID-19) Omicron Subvariant Pathogenicity
por: DeGrasse, David C, et al.
Publicado: (2023)

Effects of tea, catechins and catechin derivatives on Omicron subvariants of SARS-CoV-2
por: Shin-Ya, Masaharu, et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

‘The end’ – or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants
por: Rahimi, Farid, et al.
Publicado: (2023)

Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study
por: Mohapatra, Ranjan K., et al.
Publicado: (2023)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England
por: Strasser, Zachary H., et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariant spike N405 unlikely to rapidly deamidate
por: Beaudoin, Christopher A., et al.
Publicado: (2023)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Epidemiology and analysis of SARS-CoV-2 Omicron subvariants BA.1 and 2 in Taiwan
por: Liu, Li-Teh, et al.
Publicado: (2023)

SARS-CoV-2/Omicron subvariants: global outbreak upsurge and expected upcoming threats
por: Malik, Sumira, et al.
Publicado: (2023)

Moving targets: COVID-19 vaccine efficacy against Omicron subvariants
por: da Silva, Maria Karolaynne, et al.
Publicado: (2022)

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants
por: Desautels, Thomas A., et al.
Publicado: (2023)

Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants
por: Wang, Xue-Jun, et al.
Publicado: (2022)

Genomic evidence for reinfection with different Omicron subvariants
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants
por: Mäkelä, Anna R., et al.
Publicado: (2023)

Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
por: Roe, Tiffany L., et al.
Publicado: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Deep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
por: Alcantara, Mellissa C., et al.
Publicado: (2023)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_crv9vbrn4u6a4rr4d6o3t7u9bj